[go: up one dir, main page]

AR122013A1 - Composiciones de virus adenoasociados compatibles entre especies y métodos para su uso - Google Patents

Composiciones de virus adenoasociados compatibles entre especies y métodos para su uso

Info

Publication number
AR122013A1
AR122013A1 ARP210101222A ARP210101222A AR122013A1 AR 122013 A1 AR122013 A1 AR 122013A1 AR P210101222 A ARP210101222 A AR P210101222A AR P210101222 A ARP210101222 A AR P210101222A AR 122013 A1 AR122013 A1 AR 122013A1
Authority
AR
Argentina
Prior art keywords
methods
adeno
associated virus
species
compatible
Prior art date
Application number
ARP210101222A
Other languages
English (en)
Inventor
Aravind Asokan
Trevor Gonzalez
Lawrence Patrick Havlik
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Publication of AR122013A1 publication Critical patent/AR122013A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

Vectores de virus adenoasociados (AAV) que comprenden variantes de proteínas de la cápside, composiciones farmacéuticas, métodos para su elaboración y métodos para su administración a un sujeto.
ARP210101222A 2020-05-05 2021-05-05 Composiciones de virus adenoasociados compatibles entre especies y métodos para su uso AR122013A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063020062P 2020-05-05 2020-05-05

Publications (1)

Publication Number Publication Date
AR122013A1 true AR122013A1 (es) 2022-08-03

Family

ID=78468375

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101222A AR122013A1 (es) 2020-05-05 2021-05-05 Composiciones de virus adenoasociados compatibles entre especies y métodos para su uso

Country Status (12)

Country Link
US (3) US20230151389A1 (es)
EP (1) EP4125977A4 (es)
JP (1) JP7756439B2 (es)
KR (1) KR20230029616A (es)
CN (1) CN116096377B (es)
AR (1) AR122013A1 (es)
AU (1) AU2021268946A1 (es)
BR (1) BR112022022644A2 (es)
CA (1) CA3177869A1 (es)
IL (1) IL297577A (es)
MX (1) MX2022013963A (es)
WO (1) WO2021226267A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022022644A2 (pt) * 2020-05-05 2023-01-17 Univ Duke Composições de vírus adeno-associados compatíveis com espécies cruzadas e método de uso destas
CA3234664A1 (en) 2021-10-08 2023-04-13 Dyno Therapeutics, Inc. Capsid variants and methods of using the same
JP2025527658A (ja) * 2022-08-24 2025-08-22 リジェネックスバイオ インコーポレイテッド 組換えアデノ随伴ウイルス及びその使用
WO2024168089A2 (en) * 2023-02-07 2024-08-15 Duke University Compositions comprising aavs and methods for treating gastrointestinal diseases
EP4661916A1 (en) * 2023-02-08 2025-12-17 Ginkgo Bioworks, Inc. Gene therapy for angelman syndrome
KR20250169640A (ko) 2023-03-10 2025-12-03 디노 테라퓨틱스, 인코포레이티드 캡시드 폴리펩타이드 및 이의 사용 방법
WO2024206831A1 (en) * 2023-03-31 2024-10-03 Duke University Compositions comprising brain-tropic aavs and methods of use thereof
TW202525832A (zh) 2023-08-31 2025-07-01 美商戴諾治療公司 衣殼多肽及其使用方法(二)
WO2025171227A1 (en) 2024-02-08 2025-08-14 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
WO2025250457A1 (en) * 2024-05-28 2025-12-04 University Of Rochester Enhanced brain transduction by gene therapeutics

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
DE69941905D1 (de) 1998-11-10 2010-02-25 Univ North Carolina Virusvektoren und verfahren für ihre herstellung und verabreichung.
US7314912B1 (en) 1999-06-21 2008-01-01 Medigene Aktiengesellschaft AAv scleroprotein, production and use thereof
WO2001092551A2 (en) 2000-06-01 2001-12-06 University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
NZ545628A (en) * 2003-09-30 2009-04-30 Univ Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor
WO2007127264A2 (en) * 2006-04-28 2007-11-08 The Trustees Of The University Of Pennsylvania Scalable production method for aav
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
JP6042825B2 (ja) * 2011-02-10 2016-12-14 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 改変された形質導入プロファイルを有するウイルスベクターならびにその製造および使用の方法
US11136557B2 (en) * 2013-05-31 2021-10-05 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
US10746742B2 (en) * 2014-04-25 2020-08-18 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
EP3151866B1 (en) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimeric capsids
JP7064214B2 (ja) * 2015-09-28 2022-05-10 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 抗体回避性ウイルスベクターのための方法および組成物
CA3052829A1 (en) * 2017-02-15 2018-08-23 The University Of North Carolina At Chapel Hill Methods and compositions for gene transfer across the vasculature
EP3589277A4 (en) * 2017-02-28 2020-08-26 Adverum Biotechnologies, Inc. MODIFIED AVA CAPSIDES AND USE OF THESE LATEST
ES2966692T3 (es) * 2017-03-15 2024-04-23 Univ North Carolina Chapel Hill Vectores de virus adenoasociados poliploides y métodos de fabricación y uso de los mismos
US10550405B2 (en) 2017-03-15 2020-02-04 The University Of North Carolina At Chapel Hill Rational polyploid adeno-associated virus vectors and methods of making and using the same
EP3773743A1 (en) * 2018-04-03 2021-02-17 Stridebio, Inc. Virus vectors for targeting ophthalmic tissues
US12091435B2 (en) * 2018-04-03 2024-09-17 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
EP3793615A2 (en) 2018-05-16 2021-03-24 Voyager Therapeutics, Inc. Directed evolution of aav to improve tropism for cns
CN113438954A (zh) * 2018-10-01 2021-09-24 宾夕法尼亚州大学信托人 可用于治疗gm1神经节苷脂病的组合物
CA3133453A1 (en) 2019-03-21 2020-09-24 Daniel Mccoy Recombinant adeno-associated virus vectors
BR112022022644A2 (pt) * 2020-05-05 2023-01-17 Univ Duke Composições de vírus adeno-associados compatíveis com espécies cruzadas e método de uso destas

Also Published As

Publication number Publication date
US20240067988A1 (en) 2024-02-29
EP4125977A4 (en) 2024-09-25
BR112022022644A2 (pt) 2023-01-17
US12037598B2 (en) 2024-07-16
CN116096377A (zh) 2023-05-09
CN116096377B (zh) 2026-01-02
US12146151B2 (en) 2024-11-19
JP2023524291A (ja) 2023-06-09
AU2021268946A1 (en) 2022-12-01
TW202208631A (zh) 2022-03-01
MX2022013963A (es) 2023-02-22
IL297577A (en) 2022-12-01
JP7756439B2 (ja) 2025-10-20
US20240076695A1 (en) 2024-03-07
WO2021226267A3 (en) 2021-12-16
EP4125977A2 (en) 2023-02-08
WO2021226267A2 (en) 2021-11-11
KR20230029616A (ko) 2023-03-03
CA3177869A1 (en) 2021-11-11
US20230151389A1 (en) 2023-05-18

Similar Documents

Publication Publication Date Title
AR122013A1 (es) Composiciones de virus adenoasociados compatibles entre especies y métodos para su uso
MX2024004936A (es) Variantes de capsides de aav y sus usos.
CO2022016156A2 (es) Redirección del tropismo de las cápsides de aav
MX2024014624A (es) Variantes de capsides de aav y sus usos
AR118465A1 (es) Vectores de virus adenoasociados recombinantes
CL2023000264A1 (es) Nuevos vectores virales adeno-asociados dirigidos al hígado
BR112021020957A2 (pt) Capsídeos de vírus adenoassociado (aav) variante para liberação intravítrea
MX2024014691A (es) Enlazadores de conjugacion mejorados
MX2024009660A (es) Variantes de capside de aav y usos de las mismas.
WO2020028751A3 (en) Aav variants with enhanced tropism
CL2020002797A1 (es) Composiciones sólidas que comprenden un agonista de glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
MX2020010881A (es) Construcciones de anticuerpos anti-ror.
MX2022004146A (es) Composición farmacéutica de vector de virus adenoasociado y métodos.
CL2023001793A1 (es) Anticuerpos anti-componente de complemento y métodos de uso
MX2021012205A (es) Anticuerpos de cadena pesada que se unen al psma.
ECSP17059343A (es) ARNi VARIANTE
MX2017012097A (es) Variantes de virus adenoasociado y métodos de uso de estas.
BR112018006074A2 (pt) vetores de fator viii de vírus adeno-associado, partículas virais associadas e formulações terapêuticas compreendendo as mesmas
ECSP034439A (es) Nuevos peptidos como inhibidores de ns-3-serina proteasa del virus de la hepatitis c
BR112021012667A2 (pt) Proteínas de ligação anti-pd-1 e métodos de uso destas
MX388128B (es) Vacuna combinada para cerdos.
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
MX2025004075A (es) Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos
MX2024009250A (es) Composiciones farmaceuticas para la administracion de antigenos del virus del herpes simple y metodos relacionados
EA202190318A1 (ru) Составы вакцин, содержащие систему консервантов

Legal Events

Date Code Title Description
FA Abandonment or withdrawal